EUVIMEDScopri EUVIMED
Crossref

Mid‐term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry

Claudia Fiorina, Mauro Massussi iD, Marco Ancona iD, Matteo Montorfano, Anna Sonia Petronio, Giuseppe Tarantini, Fausto Castriota, Giuliano Chizzola, Giuliano Costa iD, Corrado Tamburino, Marianna Adamo iD

Catheterization and Cardiovascular Interventions · 2023

DOI: 10.1002/ccd.30813 ↗

At a glance

Journal article in Catheterization and Cardiovascular Interventions, 2023. Written by Claudia Fiorina and 10 co-authors. Institution: Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Scienc…. Major MEDLINE topics: Transcatheter Aortic Valve Replacement, Bicuspid Aortic Valve Disease, Heart Valve Diseases, Aortic Valve Stenosis. Cited 11 times so far (Crossref); 22 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Limited data are available on transcatheter heart valves (THVs) durability in bicuspid aortic valve (BAV) stenosis.

Aims

To evaluate evaluating 4‐year clinical and echocardiographic outcomes of patients with BAV undergoing transcatheter aortic valve implantation (TAVI).

Methods

The bicuSpid TAvi duraBILITY (STABILITY) registry is an Italian multicentre registry including all consecutive patients with BAV and severe aortic stenosis (AS), treated by means of TAVI between January 2011 and December 2017. Outcomes of interest were all‐cause death at 4‐year, over time changes in echocardiographic measurements, and THV durability according to the valve aortic research consortium (VARC)‐3 update definitions.

Results

Study population included 109 patients (50% females; mean age 78 ± 7.5 years) with a mean Society of Thoracic Surgeons Predicted Risk of Mortality score of 5.1 ± 4.3%. Median follow‐up (FU) duration was 4.1 years [interquartile range: 2.8–5.1]. The overall cumulative incidence of all‐cause death by Kaplan–Meier estimates at 4 years was 32%. Compared to baseline, a significant decrease in transprosthetic mean gradient was obtained after TAVI (54 ± 16 vs. 10 ± 5 mmHg; p < 0.001), whereas a significant increase was observed at 4‐year (13 ± 6.4 mmHg, p = 0.03). Cumulative incidence of hemodynamic valve dysfunction (HVD) was 4%. Six patients met HVD criteria: three moderate and three severe HVD. All three cases of severe HVD were clinically relevant (bioprosthetic valve failure [BVF]) with two patients receiving a reintervention (TAVI in TAVI), and one patient experiencing a valve‐related death due to endocarditis.

Conclusions

The STABILITY registry suggests that in patients with severe AS and BAV undergoing TAVI, postprocedural clinical benefits might last, over time, up to 4‐year FU. The low rates of severe HVD and BVF may support the hypothesis of good THV durability also in BAV recipient.

Subjects

MeSH terms (MEDLINE)

Transcatheter Aortic Valve ReplacementBicuspid Aortic Valve DiseaseHeart Valve DiseasesAortic Valve StenosisMitral Valve StenosisHeart Valve ProsthesisFemaleHumansAgedAged, 80 and overMaleAortic ValveConstriction, PathologicTreatment OutcomeRegistries

Author keywords

Transcatheter aortic valve implantation (TAVI)biscuspid aortic valve stenosis (BAV)follow-up

Authors and institutions

  • Cardiac Catheterization Laboratory and Cardiology, ASST Spedali Civili Brescia and Department of Medical and Surgery Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Cardio-Thoracic-Vascular Department, San Raffaele Scientific Institute, Milan, Italy.
  • Cardio Thoracic and Vascular Department, Cardiac Catheterization Laboratory, University of Pisa and Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Division of Cardiology, Department of Cardiac, Thoracic and Vascular Sciences, University of Padova, Padova, Italy.
  • Interventional Cardiology Unit, Maria Cecilia Hospital, GVM Care and Research, Maria Cecilia Hospita, Ravenna, Italy.
  • Division of Cardiology, A.O.U. Policlinico "G. Rodolico-San Marco", University of Catania, Catania, Italy.

ORCID profiles: Mauro Massussi, Marco Ancona, Giuliano Costa, Marianna Adamo

Cite

APA

Fiorina, C., Massussi, M., Ancona, M., Montorfano, M., Petronio, A. S., Tarantini, G., Castriota, F., Chizzola, G., Costa, G., Tamburino, C., & Adamo, M. (2023). Mid‐term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.30813

Vancouver

Fiorina C, Massussi M, Ancona M, Montorfano M, Petronio AS, Tarantini G, et al. Mid‐term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry. Catheterization and Cardiovascular Interventions. 2023. doi:10.1002/ccd.30813

BibTeX
@article{Fiorina2023,
  author = {Fiorina, Claudia and Massussi, Mauro and Ancona, Marco and Montorfano, Matteo and Petronio, Anna Sonia and Tarantini, Giuseppe and Castriota, Fausto and Chizzola, Giuliano and Costa, Giuliano and Tamburino, Corrado and Adamo, Marianna},
  title = {Mid‐term outcomes and hemodynamic performance of transcatheter aortic valve implantation in bicuspid aortic valve stenosis: Insights from the bicuSpid TAvi duraBILITY (STABILITY) registry},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2023},
  doi = {10.1002/ccd.30813}
}
Start for free →